Latest Conference Articles

Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPC

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

Niraparib Plus Abiraterone and Prednisone Elicits OS Benefit in BRCA1/2+ mCRPC

The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Pembrolizumab Plus Enzalutamide Delivers No rPFS or OS Benefits in mCRPC

Pembrolizumab plus enzalutamide provided no radiographic progression-free survival or overall survival improvements vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases

Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.

Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

Selpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer, according to interim findings from the phase 3 LIBRETTO-531 trial.

Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion+ NSCLC

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC

The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

Alectinib Elicits DFS Benefit in Early-Stage, Resected, ALK+ NSCLC

Treatment with the oral ALK inhibitor alectinib led to a statistically significant improvement in disease-free survival in patients with resected ALK-positive non–small cell lung cancer.

Belzutifan Generates Superior PFS, ORR in Pretreated Advanced ccRCC

Treatment with belzutifan produced improvements in progression-free survival and objective response rate vs everolimus in patients with pretreated advanced clear cell renal cell carcinoma.

Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.

Selpercatinib Significantly Improves PFS Vs Chemo With or Without Pembrolizumab in RET+ NSCLC

Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.

Perioperative Cemiplimab Demonstrates Continued Efficacy in Stage II to IV CSCC

Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma.

Lifileucel Demonstrates Efficacy in Advanced Mucosal Melanoma Following Progression on Immune Checkpoint Inhibitors

Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.

Etigilimab Plus Nivolumab Shows Activity in Recurrent/Advanced Solid Tumors, and Possible Biomarkers Emerge

Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease

Trastuzumab Deruxtecan Sustains Survival Benefits in HER2-Low Metastatic Breast Cancer

Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.

Retrospective Analysis Shows Trastuzumab Deruxtecan Improves Intracranial Responses in HER2+ Breast Cancer

Fam-trastuzumab deruxtecan-nxki elicited higher rates of intracranial responses vs comparator therapies in patients with HER2-positive metastatic breast cancer with both stable and active brain metastases.

Belzutifan Plus Cabozantinib Delivers Durable Responses in ccRCC

Belzultifan in combination with cabozantinib generated durable responses independent of International Metastatic RCC Database Consortium risk category in patients with treatment-naïve clear cell renal cell carcinoma or those who had received prior immunotherapy.

Frontline Atezolizumab Plus Chemotherapy Elicits PFS Benefit in Advanced/Recurrent Endometrial Cancer

Atezolizumab plus standard-of-care platinum-based chemotherapy, followed by maintenance therapy with atezolizumab monotherapy, improved progression-free survival vs chemotherapy plus placebo, followed by placebo maintenance therapy, in the frontline treatment of patients with advanced or recurrent endometrial carcinoma particularly in those with mismatch repair–deficient disease.

Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Sacituzumab Govitecan Demonstrates Modest Activity in Pretreated HNSCC

Sacituzumab govitecan-hziy led to modest but durable antitumor activity with predominant gastrointestinal toxicities in patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr Powles

Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer

Patients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective response rate with the addition of atezolizumab to chemotherapy and niraparib maintenance therapy.

Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC

Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Elicits PSA-PFS Improvement in mCRPC

Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan and enzalutamide led to an improvement in prostate-specific antigen progression-free survival vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab Plus Neoadjuvant Chemotherapy Produces Long-Term Survival Benefits in High-Risk TNBC

Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer.